How were Menlo Therapeutics' earnings last quarter?

Menlo Therapeutics Inc. (NASDAQ:FOMX) released its earnings results on Monday, November, 11th. The specialty pharmaceutical company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.34) by $0.07.

What other stocks do shareholders of Menlo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Menlo Therapeutics investors own include Sorrento Therapeutics (SRNE) , Amarin (AMRN) , Sangamo Therapeutics (SGMO) , Viking Therapeutics (VKTX) , CRISPR Therapeutics (CRSP) , Gilead Sciences (GILD) , Agile Therapeutics (AGRX) , Anavex Life Sciences (AVXL) , OPKO Health (OPK) and Pfizer (PFE) .

NASDAQ:FOMX

Menlo Therapeutics (FOMX) Stock Price, News & Analysis

→ The only accurate crypto trading system I know … (From Weiss Ratings) (Ad)

Free FOMX Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $2.99
▼
$2.99
50-Day Range: $2.99
▼
$2.99
52-Week Range: $1.97
▼
$4.84

Volume: N/A
Average Volume: 518,350 shs
Market Capitalization: $184.12 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Menlo Therapeutics alerts:

Ad Banyan Hill Publishing

The Best AI Stock to Own in the World Today is Trading for Just $25

“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.

See how you can invest alongside him

About Menlo Therapeutics Stock (NASDAQ:FOMX)

Foamix Pharmaceuticals Ltd., a late clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations for dermatological therapy in the United States, France, Denmark, and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline that has completed third pivotal Phase III clinical trial for the treatment of moderate-to-severe acne; and FMX103, which is in Phase III clinical trial for the treatment of moderate-to-severe papulopustular rosacea. The company's product pipeline includes FCD105 and FMX109 for the treatment of moderate-to-severe acne vulgaris; and FMX110 for the treatment of papulopustular rosacea. Foamix Pharmaceuticals Ltd. has development and license agreements with Bayer HealthCare AG; LEO Pharma A/S; Mylan N.V.; and Actavis plc. The company was founded in 2003 and is headquartered in Rehovot, Israel.

Ad Stansberry Research

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

But there's a much better move you can make to get in front of these big moves today.

FOMX Stock News Headlines

April 18, 2024 | msn.com

Camera store in downtown Menlo Park burglarized

April 17, 2024 | msn.com

Menlo Park man arrested on $1.2M human trafficking warrant

April 19, 2024 | Stansberry Research (Ad)

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

March 26, 2024 | msn.com

Menlo Park Mall adding seven new stores, restaurants this spring. Here's what's coming

March 14, 2024 | msn.com

Man arrested on suspicion of firing gun at Menlo Park home

March 4, 2024 | msn.com

Menlo, Micron represent opportunity for Ithaca's manufacturing workforce to grow

February 22, 2024 | yahoo.com

Menlo Park police report increase in home break-ins, suspects targeting ‘affluent neighborhoods’

January 29, 2024 | finance.yahoo.com

Corcept Appoints Roberto Vieira as President, Oncology

April 19, 2024 | Stansberry Research (Ad)

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

December 27, 2023 | bizjournals.com

Menlo Park builder's remedy project proposal getting bigger

December 26, 2023 | bizjournals.com

California conditionally approves Menlo Park's housing element

December 25, 2023 | msn.com

Menlo Park apartment fire kills two people, two dogs Sunday morning

December 19, 2023 | health.usnews.com

Independent Living Communities Near Menlo Park, CA

December 12, 2023 | msn.com

New citizenM Menlo Park Hotel opens in Silicon Valley, US

November 28, 2023 | tmcnet.com

Menlo Security Strengthens Executive Leadership Team with Chief Marketing Officer and Chief Financial Officer Appointments

November 27, 2023 | msn.com

Here’s What You Need to Know About The Stanford Park Hotel, Menlo Park

November 16, 2023 | markets.businessinsider.com

Menlo Ventures Closes $1.35 Billion to Invest in Companies Leading the AI Transformation

November 11, 2023 | health.usnews.com

Dr. Sun Hae Choi

November 8, 2023 | msn.com

Look: Steve Young, John Paye lead first-year Menlo girls flag football team to 15-1 season

October 29, 2023 | msn.com

Two Alarm Fire at Menlo Park Diner on Saturday Night

October 28, 2023 | foxnews.com

Head of embattled Illinois child services agency to resign at year's end

October 26, 2023 | finance.yahoo.com

Corcept Initiates MONARCH – A Phase 2b Trial in Non-Alcoholic Steatohepatitis (NASH)

October 5, 2023 | msn.com

Gain Therapeutics doses first two subjects in Parkinson’s therapy trial

September 22, 2023 | msn.com

Menlo Park street shut down due to hazmat situation

September 22, 2023 | msn.com

Discovery of ‘unknown substance’ in Menlo Park home prompts hours-long road closure

September 14, 2023 | technews.tmcnet.com

Menlo Equities and Beacon Capital Partners Break Ground on 240,000 SF Life Science Building in San Carlos, CA

September 2, 2023 | msn.com

SC native Lynden Gooch, 27, signs two-year deal with Stoke City F.C. | Local Roundup

See More Headlines

Receive FOMX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Menlo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/11/2019
Today: 4/19/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Medicinals & Botanicals
Sub-Industry: N/A
Current Symbol: NASDAQ:FOMX
CUSIP: N/A
CIK: 1606645
Web: www.foamix.com
Phone: 972-8931-6233
Fax: N/A
Employees: 80
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($1.70)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-74,160,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -100.58%
Return on Assets: -81.39%

Debt

Debt-to-Equity Ratio: 0.24
Current Ratio: 5.72
Quick Ratio: 5.72

Sales & Book Value

Annual Sales: $3.60 million
Price / Sales: 51.15
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.70 per share
Price / Book: 1.76

Miscellaneous

Outstanding Shares: 61,580,000
Free Float: N/A
Market Cap: $184.12 million
Optionable: Optionable
Beta: 1.66

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Mr. David T. Domzalski (Age 52)
CEO & Director
Mr. Ilan Hadar M.B.A. (Age 50)
MBA, CFO & Country Mang.
Ms. Mutya Harsch (Age 44)
Gen. Counsel & Chief Legal Officer
Dr. Darrell S. Rigel M.D. (Age 69)
MS, Consultant
Dr. Iain A. Stuart (Age 46)
Chief R&D Officer

Key Competitors

View All Competitors

FOMX Stock Analysis - Frequently Asked Questions

How were Menlo Therapeutics' earnings last quarter?: Menlo Therapeutics Inc. (NASDAQ:FOMX) released its earnings results on Monday, November, 11th. The specialty pharmaceutical company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.34) by $0.07.
What other stocks do shareholders of Menlo Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Menlo Therapeutics investors own include Sorrento Therapeutics (SRNE), Amarin (AMRN), Sangamo Therapeutics (SGMO), Viking Therapeutics (VKTX), CRISPR Therapeutics (CRSP), Gilead Sciences (GILD), Agile Therapeutics (AGRX), Anavex Life Sciences (AVXL), OPKO Health (OPK) and Pfizer (PFE).

This page (NASDAQ:FOMX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Menlo Therapeutics (FOMX) Stock Price, News & Analysis

About Menlo Therapeutics Stock (NASDAQ:FOMX)

FOMX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

FOMX Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info